Oramed Pharmaceuticals (FRA:OJU1) EPS (Basic): €2.27 (TTM As of Mar. 2026)


FRA:OJU1 Oramed Pharmaceuticals Inc FRA:OJU1
34 GF Score
Price €4.20
! 4 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals EPS (Basic)?

Oramed Pharmaceuticals FRA:OJU1 +16.18% 34 EPS (Basic) is €2.27 as of Mar. 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Oramed Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.81. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.27.

Oramed Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was €0.79. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.22.

Oramed Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was €0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.50.

During the past 3 years, the average EPS without NRI Growth Rate was 34.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Oramed Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 34.80% per year. The lowest was -188.40% per year. And the median was 1.85% per year.

Oramed Pharmaceuticals  (FRA:OJU1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oramed Pharmaceuticals EPS (Basic) Related Terms

Oramed Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals EPS (Basic) Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 -0.89 0.13 -0.46 1.31

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 0.28 0.99 0.20 0.81
FRA:OJU1
34GF Score
Oramed Pharmaceuticals Inc FRA:OJU1
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Oramed Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(54.699-0)/41.403
=1.32

Oramed Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(33.138-0)/40.774
=0.81

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €2.27 mean?
Oramed Pharmaceuticals (FRA:OJU1) has a EPS (Basic) of €2.27 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' EPS (Basic) too high?
Oramed Pharmaceuticals' current EPS (Basic) is €2.27. Overall, Oramed Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' EPS (Basic) compare to SPRO and PLYX?
Oramed Pharmaceuticals' EPS (Basic) of €2.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current EPS (Basic) is €2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (FRA:OJU1) has a current EPS (Basic) of €2.27. The current EPS (Basic) is €2.27. Oramed Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current EPS (Basic) is €2.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
34GF Score

Get the complete analysis for FRA:OJU1

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.20
Price